抗瘤坏死因子阿尔法疗法的有效性和耐受性在耐火性肠道贝希特病中:一项大型单中心研究
Ji Young Chang1, Jiwoo Kim2,3, Soo Jung Park2,3,4
1Department of Health Promotion Medicine, Ewha Womans University Seoul Hospital, Seoul, Korea.
抗瘤坏死因子α (抗TNF-α) 治疗显示了对耐火性肠道Behcetet治疗的有效性和耐受性.
科学领域:
- 胃肠病学 胃肠病学
- 免疫学 免疫学 免疫学
- 血管生物学 血管生物学
背景情况:
- 肠道贝切特病 (BD) 是一种慢性肠道血管疾病.
- 它经常被证明是对传统疗法的耐药性.
研究的目的:
- 评估抗瘤缩因子α (抗TNF-α) 治疗的有效性和耐受性.
- 专注于中度至重度耐火性肠道BD的患者.
主要方法:
- 对119名肠道BD患者的回顾性分析.
- 评估了临床缓解,反应和生物反应率在4,12和24个月.
- 监测的不良影响,复发率和复发的预测因素.
主要成果:
- 在4个月,12个月和24个月实现了23.5%,40.3%和42.0%的临床缓解率.
- 报告了高临床响应率 (84.0%在4个月) 和可接受的生物响应率.
- 确定了诸如高C反应蛋白和之前的手术等因素作为复发预测因素,而早期临床反应和免疫调节器的使用是保护性的.
结论:
- 抗瘤坏死因子α (抗TNF-α) 疗法是一个可行的和安全的治疗选择.
- 在治疗耐火性肠道BD方面已证明有效性和耐受性.
更多相关视频
10:21Mechanistic Insight into the Development of TNBS-Mediated Intestinal Fibrosis and Evaluating the Inhibitory Effects of Rapamycin
Published on: September 12, 2019
05:41Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model
Published on: April 6, 2022
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Drugs for Treatment of Ulcerative Colitis in IBD
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
